Matthew Bakalar

Title: Matthew Bakalar: Innovator in HLA-Binding Peptide Prediction

Introduction

Matthew Bakalar is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the prediction of HLA-binding peptides. His innovative approach combines structural biology with computational methods to enhance the accuracy of peptide binding predictions.

Latest Patents

Matthew Bakalar holds a patent for a method titled "Method for predicting HLA-binding peptides using protein structural features." This invention discloses a technique for predicting peptides that can bind to HLA molecules by utilizing the crystal structure of these molecules. The method employs an improved HLA-specific peptide docking workflow to simulate how a peptide occupies the binding pocket of an HLA molecule. Three models are trained to predict the binding of peptides to HLA molecules, demonstrating extremely high accuracy in predicting HLA-allele specific binding peptides. He has 1 patent to his name.

Career Highlights

Throughout his career, Matthew Bakalar has worked with esteemed organizations such as The General Hospital Corporation and Dana-Farber Cancer Institute Inc. His work in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Matthew has collaborated with notable professionals, including Nir Hacohen and Catherine J. Wu. These partnerships have further enriched his research and innovation in the field of peptide binding prediction.

Conclusion

Matthew Bakalar's contributions to the field of biotechnology, particularly in predicting HLA-binding peptides, showcase his innovative spirit and dedication to advancing scientific knowledge. His work continues to have a significant impact on the understanding of peptide interactions with HLA molecules.